HLA dosage effect in narcolepsy with cataplexy

Immunogenetics

Volumn 67, Issue 1, 2015, Pages 1-6

  van der Heide, Astrid ^a   Verduijn, Willem ^a   Haasnoot, Geert W ^a   Drabbels, Jos J M ^a   Lammers, Gert J ^a,b   Claas, Frans H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Autoimmune; HLA; Narcolepsy; Susceptibility

Indexed keywords

HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE;

ANTIGEN EXPRESSION; ARTICLE; CATAPLEXY; CONTROLLED STUDY; GENE DOSAGE; GENETIC SUSCEPTIBILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NARCOLEPSY; PRIORITY JOURNAL; ALLELE; AUTOIMMUNE DISEASE; CHEMISTRY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; HISTOCOMPATIBILITY TEST; HOMOZYGOTE; IMMUNOLOGY; NERVE CELL; SECRETION (PROCESS);

ALLELES; AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HISTOCOMPATIBILITY TESTING; HLA-DQ BETA-CHAINS; HOMOZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEURONS; NEUROPEPTIDES;

EID: 84925284326     PISSN: 00937711     EISSN: 14321211     Source Type: Journal    
DOI: 10.1007/s00251-014-0808-z     Document Type: Article

References (30)

1. American Academy of Sleep Medicine (2014) International classification of sleep disorders—third edition (ICSD-3). Darien, Illinois
2. Dauvilliers Y, Arnulf I, Mignot E (2007) Narcolepsy with cataplexy. Lancet 369:499–511
3. Eerligh P, van Lummel M, Zaldumbide A et al (2011) Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes. Genes Immun 12:415–427
4. Ellis MC, Hetisimer AH, Ruddy DA et al (1997) HLA class II haplotype and sequence analysis support a role for DQ in narcolepsy. Immunogenetics 46:410–417
5. Good IJ (1982) Standardized tail-area probabilities. J Stat Comp Simul 16:65–66
6. Haldane JB (1956) The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 20:309–311
7. Han F, Lin L, Li J et al (2012) HLA-DQ association and allele competition in Chinese narcolepsy. Tissue Antigens 80:328–335
8. Hong S-C, Lin L, Lo B et al (2007) DQB1*0301 and DQB1*0601 modulate narcolepsy susceptibility in Koreans. Hum Immunol 68:59–68
9. Hor H, Kutalik Z, Dauvilliers Y et al (2010) Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 1–5
10. Khalil I, Deschamps I, Lepage V et al (1992) Dose effect of cis- and trans-encoded HLA-DQ alpha beta heterodimers in IDDM susceptibility. Diabetes 41:378–384
11. Koeleman BPC, Lie BA, Undlien DE et al (2004) Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease. Genes Immun 5:381–388
12. Kwok WW, Kovats S, Thurtle P, Nepom GT (1993) HLA-DQ allelic polymorphisms constrain patterns of class II heterodimer formation. J Immunol 150:2263–2272
13. Luca G, Haba-Rubio J, Dauvilliers Y et al (2013) Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res 22:482–495
14. Lundin KE, Sollid LM, Qvigstad E et al (1990) T lymphocyte recognition of a celiac disease-associated cis- or trans-encoded HLA-DQ alpha/beta-heterodimer. J Immunol 145:136–139
15. Matsuki K, Grumet FC, Lin X et al (1992) DQ (rather than DR) gene marks susceptibility to narcolepsy. Lancet 339:1052–1052
16. Mignot E, Lin X, Arrigoni J et al (1994) DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. Sleep 17:S60–S67
17. Mignot E, Hayduk R, Black J et al (1997a) HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20:1012–1020
18. Mignot E, Kimura A, Lattermann A et al (1997b) Extensive HLA class II studies in 58 non-DRB1*15 (DR2) narcoleptic patients with cataplexy. Tissue Antigens 49:329–341
19. Mignot E, Lin L, Rogers W et al (2001) Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68:686–699
20. Nishino S, Ripley B, Overeem S et al (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39–40
21. Pelin Z, Guilleminault C, Risch N et al (1998) HLA-DQB1*0602 homozygosity increases relative risk for narcolepsy but not disease severity in two ethnic groups. US Modafinil in Narcolepsy Multicenter Study Group. Tissue Antigens 51:96–100
22. Peyron C, Faraco J, Rogers W et al (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
23. Šidàk Z (1967) Rectangular confidence region for the means of multivariate normal distributions. J Am Stat Assoc 62:626–633
24. Tafti M, Hor H, Dauvilliers Y et al (2014) DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 37:19–25
25. Thannickal TC, Moore RY, Nienhuis R et al (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474
26. Thorsby E (1997) Invited anniversary review: HLA associated diseases. Hum Immunol 53:1–11
27. Vader W, Stepniak D, Kooy Y et al (2003) The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 100:12390–12395
28. van Rooijen DE, Roelen DL, Verduijn W et al (2012) Genetic HLA associations in complex regional pain syndrome with and without dystonia. J Pain 13:784–789
29. Verduyn W, Doxiadis II, Anholts J et al (1993) Biotinylated DRB sequence-specific oligonucleotides. Comparison to serologic HLA-DR typing of organ donors in eurotransplant. Hum Immunol 37:59–67
30. Woolf B (1955) On estimating the relation between blood group and disease. Ann Hum Genet 19:251–253